4D MOLECULAR THERAPEUTICS
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
4D MOLECULAR THERAPEUTICS
Industry:
Biotechnology Genetics
Founded:
2013-01-01
Address:
Emeryville, California, United States
Country:
United States
Website Url:
http://www.4dmoleculartherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(510) 505-2680
Total Funding:
175 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
BioMarin Pharmaceutical
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Fulgent Therapeutics
Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Purigen Biosystems
Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Longevity Vision Fund
Longevity Vision Fund investment in Series C - 4D Molecular Therapeutics
MiraeAsset Financial Group
MiraeAsset Financial Group investment in Series C - 4D Molecular Therapeutics
BVF Partners
BVF Partners investment in Series C - 4D Molecular Therapeutics
Pappas Capital
Pappas Capital investment in Series C - 4D Molecular Therapeutics
Chiesi Ventures
Chiesi Ventures investment in Series C - 4D Molecular Therapeutics
Viking Global Investors
Viking Global Investors investment in Series C - 4D Molecular Therapeutics
QUAD Investment Management
QUAD Investment Management investment in Series C - 4D Molecular Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - 4D Molecular Therapeutics
Berkeley Catalyst Fund (BCF)
Berkeley Catalyst Fund (BCF) investment in Series C - 4D Molecular Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series C - 4D Molecular Therapeutics
Official Site Inspections
http://www.4dmoleculartherapeutics.com Semrush global rank: 4.03 M Semrush visits lastest month: 3.04 K
Unable to get host informations!!!
More informations about "4D Molecular Therapeutics"
4D Molecular Therapeutics - LinkedIn
4D Molecular Therapeutics | 17,969 followers on LinkedIn. Powering the Future of Genetic Medicines | 4DMT is a clinical stage biopharma company inventing and developing innovative products to ...See details»
4D Molecular Therapeutics - Crunchbase Company …
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.See details»
4DMT | Powering The Future Of Genetic Medicines
Oct 2, 2024 We are boldly innovating to unlock the full potential of genetic medicines for large market diseases. We harness the power of directed evolution to invent customized and enhanced vectors for use in our transformative …See details»
Contact - 4DMT
We welcome inquiries regarding products, partnerships and career openings. Contact 4DMT today.See details»
4DMT Announces Accelerated 4D-150 Phase 3 Development in …
2 days ago 4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre …See details»
4D Molecular Therapeutics Inc Company Profile - Overview
4D Molecular Therapeutics Inc (4DMT) is a clinical-stage biopharmaceutical company focused on developing genetic medicines to treat large-market diseases. The company’s therapy areas …See details»
4D Molecular Therapeutics Company Profile - Craft
Oct 29, 2024 4D Molecular Therapeutics has 5 employees at their 1 location and $37 k in annual revenue in FY 2024. See insights on 4D Molecular Therapeutics including office locations, …See details»
4D Molecular Therapeutics (USA) Funding: $595M - Medical Startups
Jun 25, 2025 4D Molecular Therapeutics is unlocking the full potential of the gene therapy field. Our customized AAV vectors can deliver genes to any cell in the body to eradicate...See details»
4D Molecular Therapeutics
4D Molecular Therapeutics is designing and developing transformative gene therapies for unmet medical conditions. Adeno-associated viruses (AAVs) have great potential for targeted delivery …See details»
4D Molecular Therapeutics - VentureRadar
Develops gene therapy solutions using a Therapeutic Vector Evolution platform, enabling a disease-first approach to product discovery and customized targeting of specific tissue types.See details»
4DMT Reports Full Year 2024 Financial Results, Operational …
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesSee details»
4DMT Announces Accelerated 4D-150 Phase 3 Development in
2 days ago 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage ExecutionSee details»
4DMT and Arbor Biotechnologies Establish Partnership to Co …
Jan 3, 2024 4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS DiseasesSee details»
4D Molecular Therapeutics Announces Updates on Clinical …
EMERYVILLE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed …See details»
Technology - 4DMT
The major hurdles in genetic medicine have been inefficient delivery into diseased tissues and cells, resulting in the need for high doses, expensive manufacturing, and the potential for …See details»
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME
Jan 10, 2025 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway January 10, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.See details»
Pipeline | 4DMT - 4D Molecular Therapeutics
Our diversified product pipeline spans three therapeutic areas, each of which leverages a unique and proprietary customized vector invented at 4DMT.See details»
4DMT Announces Accelerated 4D-150 Phase 3 Development in
1 day ago 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution July 02, 2025 16:05 ET | Source: 4D …See details»
An Song, PhD | 4DMT - 4D Molecular Therapeutics
Dr. Song received her PhD in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in Immunology at Stanford University, followed by an …See details»
Patients - 4DMT
The definition of “advocate” is “to support a cause or proposal.” We believe that truly advocating for patients and families requires much more than “support.” It requires commitment, …See details»